Top Story Today
Off-the-Shelf CAR-T Cracks the Solid Tumor Problem for the First Time
Every allogeneic CAR-T therapy ever tested against solid tumors has failed. Allogene just broke that streak. Its donor-derived ALLO-316, published in the Journal of Clinical Oncology, produced durable remissions in advanced kidney cancer patients who'd already exhausted other options. The longest response has been ticking past 18 months with no signs of stopping. In patients with high CD70 expression, nearly a third responded to a single infusion, and median overall survival in that subgroup hasn't been reached. Zero cases of graft-versus-host disease were reported.
Why it matters: This is the first proof that off-the-shelf CAR-T can deliver lasting responses in solid tumors, potentially reshaping the cell therapy manufacturing paradigm and opening the door to scalable, lower-cost cancer immunotherapy beyond blood cancers.
Read more →Deals and M&A
Argenx Drops $2.2 Billion on Autoimmune Biotech Forte Biosciences
Argenx is acquiring Forte Biosciences for $2.2 billion, expanding its immunology portfolio beyond FcRn biology into new autoimmune mechanisms. The deal continues a torrid pace of high-value M&A in the autoimmune space, following AbbVie's earlier Apogee acquisition, and signals that large-cap biotechs are paying premium prices to lock up next-generation inflammation assets.
Endpoints News →GSK Walks Away from $2.2 Billion Neuro Deal After Both Drugs Flopped
GSK terminated its entire neuroscience collaboration with Alector after spending $700 million upfront and watching both antibody drugs fail in clinical trials. The progranulin-boosting approach raised protein levels beautifully but did nothing for patients. Alector's stock now trades below $2.20, less than a third of what GSK originally paid just to partner.
Read more →Clinical and Regulatory
Europe Greenlights the World's First Flu-COVID Combo Vaccine
The European Commission approved Moderna's mCOMBRIAX, the first vaccine combining flu and COVID protection in a single shot, for adults 50 and older. In trials, the combo didn't just match separate vaccines; it beat them on immune response. For a company whose revenue dropped 41% year-over-year, it's a lifeline in a market Moderna sizes at $27 billion-plus annually.
Read more →Prime Medicine Wins Gene-Editing IP War Against Beam Therapeutics
An arbitration panel ruled that Prime Medicine's rare disease therapy doesn't violate its 2019 agreement with Beam Therapeutics, clearing Prime to file for human testing this quarter. Prime's stock jumped 11%; Beam's fell 6%. The ruling signals that gene-editing IP carve-outs will be interpreted narrowly, forcing tighter contracts across the sector.
Read more →Funding and Supply Chain
$715 Million in One Week: AI Drug Design and Radiopharmaceuticals Score Mega-Rounds
Chai Discovery (AI-designed antibodies) raised $400 million at a $3.8 billion valuation, tripling its worth in seven months. Days later, radiopharmaceutical developer AdvanCell closed $315 million with Eli Lilly and Sanofi as strategic investors. Both rounds signal that venture capital is concentrating heavily in platform companies with paying pharma customers.
Read more →Dr. Reddy's Semaglutide Stumble Exposes the GLP-1 Supply Chain Problem
An impurity detected during scale-up forced Dr. Reddy's to halt generic semaglutide production entirely, cutting its first-year pen target roughly in half and wiping $678 million off its market cap. The delay underscores a harsh reality: even the company that invented semaglutide struggles with manufacturing quality, and generic makers face an even steeper climb.
Read more →